SERPINB8

(redirected from CAP2)

SERPINB8

A gene on chromosome 18q21.3 that encodes a member of the serine protease inhibitor (serpin) family that regulates a variety of processes, such as complement activation, fibrinolysis, coagulation, cellular differentiation, tumour suppression, apoptosis and cell migration.
References in periodicals archive ?
C-CAM4 and CAP2 were highly induced by all three AhR ligands but have not been linked to AhR-mediated transcriptional regulation.
CYP1B1, C-CAM4, and CAP2 were consistently increased in livers of rats exposed to AhR ligands (TCDD, PeCDF, PCB126), whereas livers of PCB153-exposed rats exhibited little or no change.
Also, the authors argue that the degree of capital movement can be captured by either CAP1 or CAP2.
The Committee's positive vote followed a review of the most recent clinical data and analysis from two randomized control trials, PROTECT AF and PREVAIL, as well as from the CAP (Continued Access Protocol) and CAP2 registries.
Cited as a best practice by The Joint Commission and The Advisory Board, CAP2 features organizational assessments, benchmarking reports, and several comprehensive toolkits to help participants maximize the effectiveness and efficiency of their care teams.
By defining the capabilities and privileges of APRNs and PAs, CAP2 helps physicians, advanced practitioners and nurses work as a cohesive unit, resulting in reduced lengths of stay, improved patient safety and an overall increase of value-driven care.
Enrollment in the second trial, CAP2, was halted in mid-January 2002 pending further review of the CAP1 data.
Diamond Lane also offers a high density CAP4 quad line card with an open interface, full rate-adaptive capability and twice the density of the current CAP2 card.
VANCOUVER, July 28 /PRNewswire-FirstCall/ -- Information contained in The Company's news release of July 27th, 2005 relating to hole CAP2 on the Phillips Lake project near Thompson, Manitoba, has been determined to be incorrect.
Diamond Lane is also offering a high density CAP4 quad line card with an open interface, full rate adaptive capability and twice the density of the current CAP2 card.
Enrollment in the second pivotal, Phase III study examining the safety and efficacy of CIDECIN in the treatment of community-acquired pneumonia requiring hospitalization (the CAP2 study) has been suspended pending further review and evaluation of the CAP data to consider a North American and Western European- only trial for this indication.
Enrollment in the CAP2 trial is on track to enable planned mid-2002 regulatory filings for CIDECIN.